TY - JOUR
T1 - Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
AU - Marchetti, Claudia
AU - De Felice, Francesca
AU - Romito, Alessia
AU - Romito, Luigi Michele Antonio
AU - Iacobelli, Valentina
AU - Sassu, Carolina Maria
AU - Corrado, Giacomo
AU - Ricci, Caterina
AU - Scambia, Giovanni
AU - Fagotti, Anna
PY - 2021
Y1 - 2021
N2 - Ovarian cancer (OC) remains a fatal malignancy because most patients experience recurrent disease, which is resistant to chemotherapy. The outcomes for patients with platinum-resistant OC are poor, response rates to further chemotherapy are low and median survival is lower than 12 months. The complexity of platinum-resistant OC, which comprises a heterogeneous spectrum of diseases, is indeed far from being completely understood. Therefore, comprehending tumors’ biological behaviour to identify reliable biomarkers, which may predict responses to therapies, is a demanding challenge to improve OC management. In the age of precision medicine, efforts to overcome platinum resistance in OC represent a dynamic and vast field in which innovative drugs and clinical trials rapidly develop. This review will present the exceptional biochemical environment implicated in OC and highlights mechanisms of chemoresistance. Furthermore, innovative molecules and new therapeutic opportunities are presented, along with currently available therapies and ongoing clinical trials.
AB - Ovarian cancer (OC) remains a fatal malignancy because most patients experience recurrent disease, which is resistant to chemotherapy. The outcomes for patients with platinum-resistant OC are poor, response rates to further chemotherapy are low and median survival is lower than 12 months. The complexity of platinum-resistant OC, which comprises a heterogeneous spectrum of diseases, is indeed far from being completely understood. Therefore, comprehending tumors’ biological behaviour to identify reliable biomarkers, which may predict responses to therapies, is a demanding challenge to improve OC management. In the age of precision medicine, efforts to overcome platinum resistance in OC represent a dynamic and vast field in which innovative drugs and clinical trials rapidly develop. This review will present the exceptional biochemical environment implicated in OC and highlights mechanisms of chemoresistance. Furthermore, innovative molecules and new therapeutic opportunities are presented, along with currently available therapies and ongoing clinical trials.
KW - Innovative drugs
KW - Ovarian cancer
KW - Platinum resistance
KW - Predictive biomarkers
KW - Innovative drugs
KW - Ovarian cancer
KW - Platinum resistance
KW - Predictive biomarkers
UR - http://hdl.handle.net/10807/193844
U2 - 10.1016/j.semcancer.2021.08.011
DO - 10.1016/j.semcancer.2021.08.011
M3 - Article
SN - 1044-579X
VL - 77
SP - 144
EP - 166
JO - Seminars in Cancer Biology
JF - Seminars in Cancer Biology
ER -
